Literature DB >> 12208761

Identification of an interferon-gamma-inducible carcinoembryonic antigen (CEA) CD8(+) T-cell epitope, which mediates tumor killing in CEA transgenic mice.

John Schmitz1, Eva Reali, James W Hodge, Arti Patel, Garland Davis, Jeffrey Schlom, John W Greiner.   

Abstract

This study describes a CD8(+) T-cell line specific for a MHC class I-restricted carcinoembryonic antigen (CEA) epitope, residues 526-533, isolated from CEA transgenic (CEA.Tg) mice immunized with a recombinant vaccinia-CEA vaccine. Incubation of splenocytes from the immune CEA.Tg mice with the CEA(526-533) peptide resulted in the outgrowth of low-avidity CD8(+) T cells, which produced IFN-gamma and mediated perforin-dependent tumor cell lysis. However, the CEA peptide-specific T cells killed CEA-expressing murine colorectal tumor cells only after pretreatment of the targets with murine IFN-gamma (muIFN-gamma), and lysis was H-2D(b)-restricted and involved the Fas-FasL-mediated cytotoxic pathway. When the CEA peptide-specific T cells were used as in vivo effectors in adoptive T-cell transfer studies, muIFN-gamma treatment of the CEA.Tg mice was again required for T-cell-dependent growth suppression of CEA-expressing metastatic tumors. The results indicate that (a) vaccination of mice carrying the human CEA gene with recombinant vaccinia-CEA generates a CEA epitope-specific, CD8-dependent CTL response, (b) CEA, a normal, tissue-specific antigen, can also serve as a target for antitumor immunity after the adoptive transfer of CEA peptide-specific T cells, and (c) muIFN-gamma might be an effective cancer vaccine adjuvant by virtue of its ability to augment the susceptibility of tumor targets to cell-mediated lysis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12208761

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy.

Authors:  Benedetto Farsaci; Jack P Higgins; James W Hodge
Journal:  Int J Cancer       Date:  2011-08-08       Impact factor: 7.396

2.  Synergistical toll-like receptors activated dendritic cells induce antitumor effects against carcinoembryonic antigen-expressing colon cancer.

Authors:  Xinqiang Hong; Tiangen Dong; Jianwei Hu; Tuo Yi; Wenxiang Li; Zhen Zhang; Shengli Lin; Weixin Niu
Journal:  Int J Colorectal Dis       Date:  2012-07-10       Impact factor: 2.571

3.  Abscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation.

Authors:  James W Hodge; Hadley J Sharp; Sofia R Gameiro
Journal:  Cancer Biother Radiopharm       Date:  2012-01-27       Impact factor: 3.099

4.  Vaccination with a recombinant Saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses.

Authors:  Elizabeth K Wansley; Mala Chakraborty; Kenneth W Hance; Michael B Bernstein; Amanda L Boehm; Zhimin Guo; Deborah Quick; Alex Franzusoff; John W Greiner; Jeffrey Schlom; James W Hodge
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

5.  Induction of antitumor immunity ex vivo using dendritic cells transduced with fowl pox vector expressing MUC1, CEA, and a triad of costimulatory molecules (rF-PANVAC).

Authors:  Baldev Vasir; Corrine Zarwan; Rehan Ahmad; Keith D Crawford; Hassan Rajabi; Ken-Ichi Matsuoka; Jacalyn Rosenblatt; Zekui Wu; Heidi Mills; Donald Kufe; David Avigan
Journal:  J Immunother       Date:  2012-09       Impact factor: 4.456

6.  Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines.

Authors:  Benedetto Farsaci; Renee N Donahue; Michael A Coplin; Italia Grenga; Lauren M Lepone; Alfredo A Molinolo; James W Hodge
Journal:  Cancer Immunol Res       Date:  2014-08-04       Impact factor: 11.151

7.  The antitumor and immunoadjuvant effects of IFN-alpha in combination with recombinant poxvirus vaccines.

Authors:  Kenneth W Hance; Connie J Rogers; David A Zaharoff; Daniel Canter; Jeffrey Schlom; John W Greiner
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

8.  Targeted delivery of murine IFN-gamma using a recombinant fowlpox virus: NK cell recruitment to regional lymph nodes and priming of tumor-specific host immunity.

Authors:  Hasan Zeytin; Eva Reali; David A Zaharoff; Connie J Rogers; Jeffrey Schlom; John W Greiner
Journal:  J Interferon Cytokine Res       Date:  2008-02       Impact factor: 2.607

9.  Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen.

Authors:  James W Hodge; Jack Higgins; Jeffrey Schlom
Journal:  Vaccine       Date:  2009-05-29       Impact factor: 3.641

10.  Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine.

Authors:  Benedetto Farsaci; Helen Sabzevari; Jack P Higgins; Maria Giovanna Di Bari; Shinji Takai; Jeffrey Schlom; James W Hodge
Journal:  Int J Cancer       Date:  2010-10-01       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.